Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
TP53-mutant NSCLC | Preclinical | China | 17 Jun 2025 | |
Neuroblastoma | Preclinical | United States | 28 Apr 2025 | |
Neoplasms | Discovery | China | 22 May 2024 |